Last reviewed · How we verify
NCT05188716
Mechanisms and Biomarkers for Tumor Immunogenicity Modulation in Cervical Cancer
trial in Cervical Cancer in 30 participants. Completed in 15 January 2022.
13 October 2021
Quick facts
| Lead sponsor | Chuangzhen Chen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 10 December 2020 |
| Primary completion | 13 October 2021 |
| Estimated completion | 15 January 2022 |
| Sites | 1 location across China |
Conditions studied
- Cervical Cancer — all drugs for Cervical Cancer →
- Benign Tumor of Uterus — all drugs for Benign Tumor of Uterus →
Sponsor
Chuangzhen Chen — full company profile →
Who can join
Eligibility, any sex, with Cervical Cancer or Benign Tumor of Uterus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate mechanisms that dictate tumor immunogenicity and to explore potential biomarkers that could help predict changes of tumor immunogenicity and therapeutic response in patients with cervical cancer after chemoradiotherapy or surgery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients.
Chen J, Levy A, Tian AL, Huang X, et al · · 2025 · cited 29× · PMID 40068595 · DOI 10.1016/j.ccell.2025.02.010
Verify or expand the search:
- PubMed search for NCT05188716
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cervical Cancer
Currently open trials in the same condition.
- NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
- NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Other Chuangzhen Chen trials
Trials by the same sponsor.
- NCT07339488 — Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal · Phase 2 · active not recruiting
- NCT07071103 — Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors · Phase 2 · recruiting
- NCT06076135 — Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors · Phase 2 · active not recruiting
- NCT03744819 — Biomarkers for Prediction of Tumor Response to Radiotherapy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05188716 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chuangzhen Chen
- Last refreshed: 6 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05188716.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing